-+ 0.00%
-+ 0.00%
-+ 0.00%
Helus Pharma's HLP003 meets primary endpoint in Phase 3 depression trial
Share
Listen to the news
Helus Pharma's HLP003 meets primary endpoint in Phase 3 depression trial
  • Helus Pharma announced positive topline results from its Phase 3 APPROACH trial of HLP003 as an adjunctive treatment for major depressive disorder.
  • HLP003 met the primary and key secondary endpoints, reducing depressive symptoms versus placebo from Day 2 through Week 12.
  • Response and remission rates also improved significantly compared with placebo.
  • Treatment was generally well tolerated, with three treatment-related serious adverse events reported; no new safety signals emerged.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cybin Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160700PRIMZONEFULLFEED9878156) on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending